Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0000899243-20-027692)

Filing Details

Accession Number:: 0000899243-20-027692
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-10-06 21:26:01
Reporting Period:: 2020-10-06

Accepted Time:: 2020-10-06 21:26:01
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1662579	C4 Therapeutics Inc.	CCCC	Biological Products, (No Disgnostic Substances) (2836)	475617627

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1825124	Malcolm Salter	C/O C4 Therapeutics, Inc. 490 Arsenal Way, Suite 200 Watertown MA 02472		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-10-06	11,856	$0.00	11,856	No	4	C	Direct
Common Stock	Acquisiton	2020-10-06	2,823	$0.00	14,679	No	4	C	Direct
Common Stock	Acquisiton	2020-10-06	1,315	$19.00	15,994	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Direct
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2020-10-06	100,000	$0.00	11,856	$0.00
Common Stock	Series B Preferred Stock	Disposition	2020-10-06	23,809	$0.00	2,823	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Direct
0			No	4	C	Direct

Footnotes

Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.